CITATION REPORT List of articles citing

Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III)

DOI: 10.1111/joic.12005 Journal of Interventional Cardiology, 2013, 26, 107-13.

Source: https://exaly.com/paper-pdf/55383058/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
26	Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention. <i>Circulation: Cardiovascular Interventions</i> , 2013 , 6, 354-61	6	44
25	Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials. <i>Cardiovascular Revascularization Medicine</i> , 2014 , 15, 315-22	1.6	9
24	Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?. <i>American Heart Journal</i> , 2014 , 168, 611-21	4.9	29
23	Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials. <i>American Heart Journal</i> , 2014 , 167, 401-412.e6	4.9	19
22	Early stent thrombosis with bivalirudin in patients undergoing percutaneous coronary intervention. A meta-analysis of randomised clinical trials. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 1010-20	7	14
21	Fondaparinux vs. enoxaparin in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) treated with percutaneous coronary intervention and tirofiban: an exploratory study in China. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015 , 40, 584-589	2.2	6
20	Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015 , 10, e0127832	3.7	11
19	Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes. <i>Open Heart</i> , 2015 , 2, e000258	3	9
18	Bivalirudin in stable angina and acute coronary syndromes. <i>Pharmacology & Therapeutics</i> , 2015 , 152, 1-	10 13.9	5
17	Risk of Stent Thrombosis and Major Bleeding with Bivalirudin Compared with Active Control: A Systematic Review and Meta-analysis of Randomized Trials. <i>Thrombosis Research</i> , 2015 , 136, 1087-98	8.2	11
16	Frequency and predictors of thrombus inside the guiding catheter during interventional procedures: an optical coherence tomography study. <i>International Journal of Cardiovascular Imaging</i> , 2015 , 31, 239-46	2.5	3
15	Heparin is Not Inferior to Bivalirudin in Percutaneous Coronary Intervention-Focusing on the Effect of Glycoprotein IIb/IIIa Inhibitor Use: A Meta-Analysis. <i>Angiology</i> , 2015 , 66, 845-55	2.1	7
14	Bivalirudin as compared to unfractionated heparin in patients undergoing percutaneous coronary revascularization: A meta-analysis of 22 randomized trials. <i>Thrombosis Research</i> , 2015 , 135, 902-15	8.2	15
13	Bivalirudin Versus Unfractionated Heparin in Acute Coronary Syndromes: An Updated Meta-analysis of Randomized Trials. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016 , 69, 732-45	0.7	3
12	Intracoronary Bivalirudin Bolus in ST-Elevation Myocardial Infarction Patients Treated with Primary Angioplasty: Theoretical Bases, Clinical Experience, and Future Applications. <i>American Journal of Cardiovascular Drugs</i> , 2016 , 16, 391-397	4	1
11	Bivalirudina frente a heparina no fraccionada en slidromes coronarios agudos: un metanlisis actualizado de ensayos aleatorizados. <i>Revista Espanola De Cardiologia</i> , 2016 , 69, 732-745	1.5	10
10	Meta-Analysis of Effects of Bivalirudin Versus Heparin on Myocardial Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2016 , 117, 1256-	-6 ể	15

CITATION REPORT

9	Intracoronary vs intravenous bivalirudin bolus in ST-elevation myocardial infarction patients treated with primary angioplasty. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016 , 5, 487-96	4.3	1
8	The Rise and Fall of Anticoagulation with Bivalirudin During Percutaneous Coronary Interventions: A Review Article. <i>Cardiology and Therapy</i> , 2017 , 6, 1-12	2.8	1
7	Bleeding associated with the management of acute coronary syndromes. <i>Heart</i> , 2017 , 103, 546-562	5.1	5
6	Safety, efficiency and cost effectiveness of Bivalirudin: A systematic review. <i>World Journal of Cardiology</i> , 2017 , 9, 761-772	2.1	2
5	Acute Myocardial Infarction: STEMI and NSTEMI. 2018, 123-146		О
4	Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2019 , 93, 241-247	7 2.7	5
3	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 348-362	7	8
2	The Influence of the Duration of Acute Coronary Syndrome on the Outcomes of Endovascular Treatment. <i>Ukrainian Journal of Cardiovascular Surgery</i> , 2021 , 43-48	0.1	
1	Bivalirudin in Patients Undergoing PCI: State of Art and Future Perspectives. <i>Translational Medicine</i> @ UniSa, 2016 , 14, 54-63	0.5	1